370 related articles for article (PubMed ID: 12090748)
1. Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
Chang WC; Harrington RA; Simoons ML; Califf RM; Lincoff AM; Armstrong PW;
Eur Heart J; 2002 Jul; 23(14):1102-11. PubMed ID: 12090748
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
Fintel DJ; Ledley GS
Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
[TBL] [Abstract][Full Text] [Related]
3. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
Damman P; van Geloven N; Wallentin L; Lagerqvist B; Fox KA; Clayton T; Pocock SJ; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ
JACC Cardiovasc Interv; 2012 Feb; 5(2):191-9. PubMed ID: 22361604
[TBL] [Abstract][Full Text] [Related]
4. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
[TBL] [Abstract][Full Text] [Related]
5. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
[TBL] [Abstract][Full Text] [Related]
6. Age and outcome after acute coronary syndromes without persistent ST-segment elevation.
Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Harrington RA
Am Heart J; 2000 May; 139(5):858-66. PubMed ID: 10783220
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
Brown RE; Henderson RA; Koster D; Hutton J; Simoons ML
Eur Heart J; 2002 Jan; 23(1):50-8. PubMed ID: 11741362
[TBL] [Abstract][Full Text] [Related]
8. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.
Gibson CM; Kirtane AJ; Murphy SA; Rohrbeck S; Menon V; Lins J; Kazziha S; Rokos I; Shammas NW; Palabrica TM; Fish P; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):668-75. PubMed ID: 16996831
[TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes after percutaneous coronary intervention among different coronary subsets (stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction).
Loh JP; Pendyala LK; Kitabata H; Torguson R; Omar A; Minha S; Chen F; Satler LF; Pichard AD; Waksman R
Am J Cardiol; 2014 Jun; 113(11):1794-801. PubMed ID: 24837256
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Peterson JG; Topol EJ; Roe MT; Sapp SK; Lincoff AM; Deckers JW; Blackstone EH; Harrington RA; Califf RM; Lauer MS
Am J Cardiol; 2001 Mar; 87(5):532-6. PubMed ID: 11230834
[TBL] [Abstract][Full Text] [Related]
11. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
12. [Treatment strategy of unstable angina and non-ST-segment elevation myocardial infarction].
Zaliūnas R
Medicina (Kaunas); 2002; 38 Suppl 2():11-4. PubMed ID: 12560610
[TBL] [Abstract][Full Text] [Related]
13. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Boersma E; Pieper KS; Steyerberg EW; Wilcox RG; Chang WC; Lee KL; Akkerhuis KM; Harrington RA; Deckers JW; Armstrong PW; Lincoff AM; Califf RM; Topol EJ; Simoons ML
Circulation; 2000 Jun; 101(22):2557-67. PubMed ID: 10840005
[TBL] [Abstract][Full Text] [Related]
14. ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes A substudy of the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Trial.
Windhausen F; Hirsch A; Tijssen JG; Cornel JH; Verheugt FW; Klees MI; de Winter RJ;
J Electrocardiol; 2007; 40(5):408-15. PubMed ID: 17604045
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
Brown R; Armstrong P;
Can J Cardiol; 2003 Feb; 19(2):161-6. PubMed ID: 12601441
[TBL] [Abstract][Full Text] [Related]
17. Eptifibatide and tirofiban: new preparations. Limited benefit.
Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
19. Prompt use of integrilin (eptifibatide) for unstable angina/subendocardial myocardial infarction: abrupt resolution of chest discomfort marked by brief reperfusion arrhythmias and subsequent stabilization.
Fireman AS
J Invasive Cardiol; 2000 Dec; 12 Suppl D():3D-4D. PubMed ID: 11156712
[No Abstract] [Full Text] [Related]
20. [Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].
Zeymer U; Zahn R; Siegler KE; Senges J
Herz; 2004 Nov; 29(7):651-5. PubMed ID: 15580318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
